- Home
- CTO vs CRMD Comparison
CTO vs CRMD Comparison
Compare CTO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | CRMD |
|---|---|---|
| Founded | 1902 | 2006 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 643.7M | 561.8M |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | CTO | CRMD |
|---|---|---|
| Price | $18.69 | $6.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $21.50 | $14.67 |
| AVG Volume (30 Days) | 261.6K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.92% | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 2.04 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | $7.63 | $1.10 |
| Revenue Next Year | $2.76 | N/A |
| P/E Ratio | ★ N/A | $3.28 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $15.07 | $5.60 |
| 52 Week High | $20.25 | $17.43 |
Technical Indicators
Market Signals| Indicator | CTO | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 35.90 |
| Support Level | $17.29 | N/A |
| Resistance Level | $19.07 | $7.44 |
| Average True Range (ATR) | 0.38 | 0.29 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 16.38 | 18.63 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.